Description:SGI-1776 is a small molecule inhibitor primarily known for its role as a selective inhibitor of the protein kinase PIM (proviral integration site for Moloney murine leukemia virus). It has garnered attention in cancer research due to its potential to interfere with cell proliferation and survival pathways, particularly in hematological malignancies and solid tumors. SGI-1776 exhibits a unique mechanism of action by targeting the ATP-binding site of PIM kinases, thereby inhibiting their activity and leading to the induction of apoptosis in cancer cells. The compound is characterized by its relatively low molecular weight and specific structural features that enhance its binding affinity to the target kinase. Additionally, SGI-1776 has been evaluated in preclinical studies for its efficacy and safety profile, showing promise as a therapeutic agent. However, further research is necessary to fully understand its pharmacokinetics, potential side effects, and overall therapeutic potential in clinical settings.
Please enquire for more information about N-((1-Methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine including the price, delivery time and more detailed …
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![Imidazo[1,2-b]pyridazin-6-amine, N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-](https://static.cymitquimica.com/products/IN/thumb/DA0007LT.jpg)
![N-((1-Methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine](https://static.cymitquimica.com/products/3D/thumb/FM43363.jpg)
